**Background**
Bronchial diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are characterized by airway inflammation and constriction, which significantly impair respiratory function and quality of life. A key mechanism in the regulation of airway tone is the activation of muscarinic receptors by acetylcholine, which leads to bronchoconstriction. Therefore, targeting these receptors with antagonists is a critical strategy for achieving bronchodilation and protecting the pulmonary system. In this context, we will introduce a muscarinic receptor antagonist – Glycopyrrolate.
**Definition**
Glycopyrrolate (Glycopyrronium bromide) is a quaternary ammonium derivative that functions as a muscarinic receptor antagonist. According to the Glycopyrrolate description, this compound is utilized primarily in the research of bronchial diseases due to its bronchoprotective effects and its ability to influence blood pressure.
**In Vitro and In Vivo Studies**
The Glycopyrrolate biological activity has been demonstrated across various experimental models. In terms of Glycopyrrolate In Vitro studies, the application of Glycopyrrolate (1-10 nM for 30 min) has shown a protective effect on both large and small airways in guinea pig lung slices. These findings suggest its potential for mitigating intrapulmonary airway constriction.
Regarding Glycopyrrolate In Vivo research, the compound has been evaluated for its cardiovascular effects in anesthetized dogs. Administration of Glycopyrrolate (0.005-0.01 mg/kg via intravenous injection, as a single dose or a second dose if heart rate is below 70 beats/min) produces a beneficial effect on blood pressure. Specifically, dosages of 0.005 mg/kg and 0.01 mg/kg resulted in a significant increase in heart rate (HR), as well as significant increases in systolic, diastolic, and mean blood pressure above baseline values. For researchers seeking detailed Glycopyrrolate technical information, these results highlight the compound’s systemic physiological impact. In conclusion, Glycopyrrolate is a potent muscarinic receptor antagonist that provides significant bronchoprotection and cardiovascular modulation.
Keywords
Glycopyrrolate, 596-51-0, Glycopyrronium, mAChR, Muscarinic acetylcholine receptor, Chronic obstructive pulmonary disease, Anesthetized dogs, Anticholinergic, Inhibitor, inhibitor, inhibit
References
[1] Maarsingh H, et al. Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction [J]. Cells, 2021, 10(5): 1237.
[2] Dyson D H, et al. Dose effect and benefits of glycopyrrolate in the treatment of bradycardia in anesthetized dogs [J]. The Canadian Veterinary Journal, 1999, 40(5): 327.
[3] Hansel T T, Neighbour H, Erin E M, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma [J]. Chest, 2005, 128(4): 1974-1979.